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Conclusions: 1) LOTS pts show non-stationary TWA more frequently 
than stnllonan/ TWA, Usually. 30-40 boats out of 128 wore alternating. 2) 
Our correlative method was more effective thnn SM In non.stationary TWA 
detection, 3) Non.stntlonnry TWA is associated with higher henri rate, 
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~ Trestment of Patients With Hyparcholesterolemlc 
~nd Without Coronary Disease With Pravastetln 
i )eer~ssee Thrombue Format ion Under Dynamle 
Flow Condltlona 
G Dang(~s, J A, Ambrose, D,A, Smith, A,H, Un0~r, C. Fief, JH, Shno, 
P, Memi, J,T, Fallen, J,H, Chesobre, J,J, Bndimon, CaM~ova~c.lar Instmae. 
Mount SInni School of Medlcfne, N,~w York, USA 
Backgt~und: Lowonng cholesterol (C) ducroases platolel reactivity *n core. 
~ary d~soa~ (CAD) patients, but ~t~ affect on non.CAD patients l~an not boon 
previously descllbod, 
Mefho~l,~: We prospectively studied 40 stable pnl~ont~ wlll~ untreated 
LDL.C - 145 mg/dl CAD pntlonts received Pravnstatm (Pray), add non-CAD 
patlonls were rondoml..'ed to Pray vs Placebo (da~iblo.bllnd) All patients 
wore on AHA step I dial Tltrombus formalion w~s assessed blif~dly with a 
prevleusly valld,11od oX.vlvo pellUSlOn chamber system: nen.aalicoagulatod 
blood w~s passed directly from the pntienl's veln over a 8tnodnrd subslrnto 
(poroine nellie medin), under oontrellod theologic condlt,ons mlmicktng mild 
arterlnl stenosls (shoat rate 16908 ~) Poduslens wore podom~od at base- 
I~no, 3, and 6 months, Spoclmnos were stamod with CME, and for fibrmogon 
The oross.socllennl Ihrembus area (TA, in am" . t0 '~) way pl~nimotorod 
Re.qul~: Beth Pray groups shewed decreased LDL.C by 30",, wilhm 6 
w~ok~ (1Be to 126 mg/dl, p - 0,001 vs baseline), nnd decreased TA (table) 
Placebo produced no chnnges in either LDL-C or TA .',LDL-C and ,',TA wore 
modestly correlated (r - 0,49: p - 0005). 
~t~t3ohoo TA 3 f!lol'dh "[A (~ inonll'l TA 
Pray, .CAD(n. t6t 125 t ~ 1 109 t 29' 105 i 38"" 
Pray, CAD(n= 121 146 t 34 118 t ~3"  104 ~ 28"" 
Plclcebo, CAD (n = 12) 1221 19 1281~7 132145 
' p , n 07, " p • 004 vs basohno Values ,:,in moon I SD 
Conclusion: Pray therapy signill~;antly decreased ox-wvo thrombus lorma- 
tton in high LDL-C pallents, with and without CAD, This may. m part, explain 
ff~o beneficial effects el Pray m primary as well as secondary prevention of 
CAD 
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~ Lipid Lower ing Therapy  Reduces Blood 
Thrombogenlclty In Hypemholesterolemlc Patients: 
Effect of  S lmvastat ln  
U, Rauch, J.J. Badimon, DA. Vomhheimer, L Guzman, K, Harris, P. Harris, 
D.A, Sandier, J,T. Fallen, V, Fuster, J,H, Chesebro. Cardiovascular Institute. 
Meant Sinai School of Medscine, New York. NY LISA 
Lipid reduction ~mproves chmcal outoome of CAD patients despite minor 
angiographtc plaque regression. Normalization of endothehal function and 
plaque stabilization are two of the proposed mechanisms, We hypothesize 
that lipid reduction modulates blood thrombogenlcity. Blood thrembogenicity 
was measured as thrombus formation (THR) in an ex viva perlusion chamber. 
Hyperlipidemic patients (10 with and 5 without CAD) with total cholesterol 
(Cho) -.220 m~dl and LDL ~ 140 mg/dl at baseline and after 3- months 
treatment with simvastatin (20 me/day) were studied, Blood was perfused 
directly trem the psttent into the chamber at shear conditions typical of a 
mild coronary stenosts (1690/s) for 5 minute periods, Porcine aortic tuni~a 
media (model of severe arterial injury) served as the thrombogenic sub- 
strate Thrombus formation was measured as area !Hm2/mm), analyzed by 
2 independent blinded observers using computer-assisted planimetr~. 
Pallents basel':,.,: 3-months 
Cho LDL Thromt~us Cho LDL Thrombus 
CAD 253 189 10482 167" 106' 8605' 
No-CAD 277 205 9988 183' 110" 7891' 
All P15 261 172 10317 194" 108' 8366' 
• p - 005 
Lipid reduction by 8tmwlstntin reduces blood thrombogenicity, It was 
proviously suggosled that this effect is exclusive to pmvasttltin, Our rOsuffs 
indicate thrd the antlthrombotto effect t8 mediated by lipid reduction and 
Independent ol Ilto hypol*pidemic agent used, 
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~ Elevation of Plasmlnogen Activator Inhibitor "~/pe-1 
(PAl-l) in Normal Subjects by Induction of 
Hyperlnmullnemle With Hyperglycemia end 
Hypertrlglyeerldemla 
J, Calles.Eat~andon, S, Mirt, a, I~,E, ~obot, D J  Schnoide_r, Umver~i~., at
Vermont, Ehlrllngfon, V~, USA 
Hypofibrinolysis caused by Increased PAl.1 l!as boon implicated in the yes. 
culopathy of type ~ diabetes, typified by lnoroased insulin, g!gcose and 
triglycnrides, HowovQr, short 10rm infusions el insulin have not increased 
PAI.I in normal subie(~ts. We hylPothesi:'ed that induction el increased m. 
sulin accompanied by increased glucose and tnglycondos would lacrosse 
PAl.l, Acco~ingty 30%, glucose and 10% !ntrallpid wore infused tot 6 hours 
In tO normal lean Indlvld.als (54 t 3 y) resul!ing in inc~feased insuhn (42 
5 t~U/dL), ghlcose (200 ! 24 regfdl) and tnglycondos (425 t 45 mg~dl) 
simulating changes In lypo 2 d,abateS. 
R~sldt,'~. In c~ntrast o results wllh Inluslon el sahna alone [n = lb) and 
noglycemtc bypesnsullnemlc lamps (n = 10, serum insulin -= 8g ~- 7 j~UfdL), 
PAI.I m bleed increased signtlicanl!y 6 hr alter the onset el infusion t l5 
5 ngtml, p . 0.0,5 vs basohno = 74 t 11, saline 6 hr = 3.4 .* 1 I and 
msuhn 31; ,o 0 hr = 3.7 t 0.8) and remtlmod elevated for an additional 6 hr 
(combined infusion = 130 t 3~0 ng~ml, sahne = 6.7 1 2 ng'ml, insulin alone 
= 7,0 t 1 7 ng!ml, p = 006). 
Concl¢tstons: Our data suggest thai combmed hyPeensulinomia, hyper- 
tnglyeondemia and hyperglycemia m likely to contobute to bypolibenob/sls 
of type 2 diabetes by increasing the blood levels el PAl-1. Moreover, these 
instills undomcore the potential importance el moddymg insulin resistance 
as well as achieving glycemic and Iipidomic control in individuals wOh lype 2 
diabetes 
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[844-41 Benef ic ia l  Ef fect  of Estrogen Therapy on 
Flbrinotysis Is Independent of Changes in 
Low-Density Llpoprotein Levels 
KK. Koh, MN Bui, L. Hathaway. R.O. Cannon III NHLBI. NIH. Bethesda. 
MD. USA 
We have previously shown that oral coniugated equine estrogen (CEE) 
reduces ptasminogen activator Inh~b~tor (PAl-l) levels m postmenopausal 
women, an effect associated wdh proportionate increases .r degradabon 
products of fibnn However, oral estrogen reduces tow-density Itpopmtem 
cholesterol (LDL-C) levels that may account for PAl-1 effects, as oxidized 
LI.JL stimulates endothelial synthesis el PAl-1 in cell culture expenments. 
To assess the importance el LDL on PAl-l, we administered CEE 0.62,5 
me, slmvastatin 10 me, or the combination daily for 6 weeks each to 2,5 
hypemholesterolemic (LDL = 165 :~ 37 mg/dL; mean ± SD) postmenopausal 
women in a randomized, double-blind, dout~le-crossover study. Data = % 
change Item respective pretreatment values. 
CEE Simvastatln CEE/SLmvastatm 
LDL-C 1, = 11" 24 ~ 14 `~ 33 ~ 13"' 
ApoB 8 ~ 8" 23 ~ t0' ' 28 = 11" " 
PAl-1 22 ± 47'* .27 r 85 23 ~- 42-" 
'P - O 001, "'P - O 00.5 ""P . O 02 vs respochvo prelroatment basehne values: " P 
0 an5 vs CEE 
Only therapy including CEE reduced PAl-1 antigen levels, despite a 
greater effect of slm,,d~idon on reductiL, n in LDL-C and apolipoprotein B 
levels Further, there was no synergism of combined CEE and simvcslalin 
therapy on PAI-t levels. These data suggest that estrogen reduces PAl-1 
levels independent of changes in LDL. This primary effect of CEE on libn- 
nolytic potential may favor its use in hypercholesterolemic postmenopausal 
women, even it they are already on lipid-lowering therapy. 
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1 844-5J  Low-Dose  Estrogen Improves  Serum Lipids,  
Homocystelne, and F ibr ino lys ls  Wi thout  Alter ing 
Markers of  Hemostas is  in E lder ly Men 
S. Girt. P.D. Thompson, J.H. Centers, P. Taxel, J. elves. R. Allen, G. Ens. 
A,H.B. Wu. D.D. Waters. Hartford Hospital, University of Connecticut. 
Hartford. CT. USA 
The effect of estrogen on cardiovascular isk factors in men is not well defined. 
